Overview

Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient

Status:
Enrolling by invitation
Trial end date:
2023-12-06
Target enrollment:
Participant gender:
Summary
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Phase:
N/A
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Pembrolizumab